| High | $29.00 |
|---|---|
| Low | $5.00 |
| Average | $15.83 |
| Current Price | $3.8900 |
Do analysts agree on ocular therapeutix (OCUL) stock's target price?
The 12 analysts offering price forecasts for Ocular Therapeutix have a median target of 20.83, with a high estimate of 33.00 and a low estimate of 10.00. The median estimate represents a 17.81 difference from the last price of 3.71. Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock.
Is OCUL stock a buy or sell?
[Read more...] According to 7 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 21.14, which is an increase of 220.30% from the latest price.
What was the 52-week low for ocular therapeutix stock?
According to the current price, Ocular Therapeutix is 124.92% away from the 52-week low. What was the 52-week high for Ocular Therapeutix stock? The high in the last 52 weeks of Ocular Therapeutix stock was 15.27. According to the current price, Ocular Therapeutix is 24.30% away from the 52-week high.
Is there an upside for ocular therapeutix (OTX) stock?
According to analysts' consensus price target of $24.00, Ocular Therapeutix has a forecasted upside of 266.4% from its current price of $6.55. Ocular Therapeutix has only been the subject of 4 research reports in the past 90 days. Ocular Therapeutix has received 408 “outperform” votes. (Add your “outperform” vote.)
Is Ocular Therapeutics a good stock to buy?
Ocular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What is projected stock price?
The projected stock price is the result of many assumptions about earnings growth. Anything that impacts the company's revenues, such as anticipated seasonal slowing, could reduce earnings. Conversely, improved efficiencies that reduce costs could cause greater earnings improvements and reflect in the stock price.
Does stock price predict?
Stock Price Forecast The 13 analysts offering 12-month price forecasts for Hasbro Inc have a median target of 113.00, with a high estimate of 128.00 and a low estimate of 85.00. The median estimate represents a +29.80% increase from the last price of 87.06.
Which stock has highest forecast?
TickerCompanyForecast ROAPDCEPDC ENERGY INC35.47%CLNNCLENE INC1,127.36%ITCBCORPBANCA2,485.44%FANHFANHUA INC337.53%33 more rows
Will the Stock Market Crash 2022?
The S&P 500 index edged 0.9 percent lower Thursday to bring its 2022 losses to 20.6 percent. The tech-heavy Nasdaq, which fell 1.3 percent, has tumbled nearly 30 percent this year, while the Dow Jones industrial average's 0.8 percent drop put its year-to-date decline near 15 percent.
Has stock buy or sell?
The consensus among 4 Wall Street analysts covering (NASDAQ: HAS) stock is to Strong Buy HAS stock.
Should I invest in Hasbro?
Hasbro, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of HAS, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
Is Hastings technology metals a good investment?
Consensus from 2 of the Australian Metals and Mining analysts is that Hastings Technology Metals is on the verge of breakeven. They anticipate the company to incur a final loss in 2022, before generating positive profits of AU$5.5m in 2023. So, the company is predicted to breakeven approximately 2 years from now.
Should I buy or sell Ocular Therapeutix stock right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently...
What is Ocular Therapeutix's stock price forecast for 2022?
4 Wall Street research analysts have issued 1 year price targets for Ocular Therapeutix's shares. Their forecasts range from $10.00 to $29.00. On a...
How has Ocular Therapeutix's stock price performed in 2022?
Ocular Therapeutix's stock was trading at $6.97 at the beginning of 2022. Since then, OCUL shares have decreased by 47.1% and is now trading at $3....
When is Ocular Therapeutix's next earnings date?
Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Ocu...
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earn...
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the following people: Mr. Antony Mattessich , Pres, CEO & Director (Age 55, Pay $1.03M) ( LinkedIn...
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Cassava Sciences (SAVA) , Myovant Sciences (MYOV) , MannKind (MNKD) , Zentalis Ph...
What other stocks do shareholders of Ocular Therapeutix own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedi...
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
Is Ocular Therapeutix stock a Buy, Sell or Hold?
Ocular Therapeutix stock has received a consensus rating of buy. The average rating score is and is based on 11 buy ratings, 1 hold ratings, and 0...
What was the 52-week low for Ocular Therapeutix stock?
The low in the last 52 weeks of Ocular Therapeutix stock was 2.93. According to the current price, Ocular Therapeutix is 122.53% away from the 52-w...
What was the 52-week high for Ocular Therapeutix stock?
The high in the last 52 weeks of Ocular Therapeutix stock was 14.96. According to the current price, Ocular Therapeutix is 24.00% away from the 52-...
What are analysts forecasts for Ocular Therapeutix stock?
The 12 analysts offering price forecasts for Ocular Therapeutix have a median target of 20.83, with a high estimate of 33.00 and a low estimate of...
When will Ocular Therapeutix report results?
What is ocular therapeutix?
(Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter financial results on Wednesday, May 5, 2021. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.
What is Oculus 2021?
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:
When is Ocul earnings call 2021?
(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, entered into a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents aimed at the treatment of Dry Age-related Macular Degeneration (dAMD).
Share your Analysis on OCUL
(NASDAQ:OCUL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time.
Company Profile
Join our contributor community and share your insights with millions of readers across the globe. Submit an article now
Stock Price Forecast
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.
Analyst Recommendations
The 7 analysts offering 12-month price forecasts for Ocular Therapeutix Inc have a median target of 20.00, with a high estimate of 30.00 and a low estimate of 14.00. The median estimate represents a +304.86% increase from the last price of 4.94.
About OCUL
The current consensus among 7 polled investment analysts is to Buy stock in Ocular Therapeutix Inc. This rating has held steady since August, when it was unchanged from a Buy rating. Move your mouse over past months for detail
Analyst Forecast
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.
News
According to 7 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 21.14, which is an increase of 285.77% from the latest price.
What is ocular therapeutix?
BEDFORD, Mass.-- (BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
What time do you trade in the pre market?
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop thera
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Analyst price target for OCUL
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
OCUL earnings per share forecast
Based on 3 analyst s offering 12 month price targets for Ocular Therapeutix Inc.
OCUL revenue forecast
What is OCUL 's earnings per share in the next 3 years based on estimates from 5 analyst s?
OCUL revenue growth forecast
What is OCUL 's revenue in the next 3 years based on estimates from 4 analyst s?
